Advances in sickle cell therapies in the hydroxyurea era.

ABSTRACT: In the hydroxyurea era, insights into mechanisms downstream of erythrocyte sickling have led to new therapeutic approaches for patients with sickle cell disease (SCD). Therapies have been developed that target vascular adhesion, inflammation and hemolysis, including innovative biologics directed against P-selectin and invariant natural killer T cells. Advances in hematopoietic stem cell transplant and gene therapy may also provide more opportunities for cures in the near future. Several clinical studies are underway to determine the safety and efficacy of these new treatments. Novel approaches to treat SCD are desperately needed, since current therapies are limited and rates of morbidity and mortality remain high.

SUBMITTER: Field JJ 

PROVIDER: S-EPMC4374518 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature